All Blogs
Jul 12, 2024
Eli Lilly strengthening its Gastroenterology portfolio post Acquisition of Morphic. Tracking competitors and alliances in inflammatory bowel disease (IBD).
In a strategic move aimed at bolstering its portfolio in inflammatory bowel disease (IBD) treatments, Eli Lilly and Company has announced a definitive agreement to acquire Morphic Holding for approximately USD 3.2 billion. The purchase price represents a 79% premium to Morphic’s closing stock price. Post the tender...
Read More...
May 08, 2025
Top 7 Breakthrough Drugs for Ulcerative Colitis Treatment
Ulcerative colitis is a type of inflammatory bowel disease of unknown origin that targets the lining of the colon. Symptoms typically include diarrhea, abdominal pain, discomfort, and the presence of blood in the stool. The severity of the condition can vary, with inflammation affecting just the rectum, extending t...
Read More...
Jul 11, 2024
Cordis FDA Approval for MYNX CONTROL VENOUS Vascular Closure Device; Forma Medical’s Optimal Plating System FDA Approval; Virpax’s Swine Model Pilot Study Positive Results; SetPoint Medical Positive Topline Results from Pioneering RESET-RA Study; Signature Orthopaedics Partnered with THINK Surgical; Nusano and PharmaLogic Formed Strategic Supply Agreement
Cordis Secured FDA Approval for MYNX CONTROL VENOUS Vascular Closure Device, Expanding Proven MYNX Technology to Mid-Bore Venous Puncture Sites On July 9, 2024, Cordis, a leading company in cardiovascular and endovascular technology, received FDA approval for its MYNX CONTROL™ VENOUS Vascular Closure Device. Thi...
Read More...
Jul 10, 2024
Gummy Vitamins: A Sweet Solution to Nutrient Deficiencies?
In recent years, gummy vitamins have surged in popularity, becoming a staple in many households. Originally designed for children, these chewable, sweet, and often colorful supplements are now widely consumed by adults as well. Their popularity is not just a trend; it's a reflection of their convenience, taste, and...
Read More...
Jul 09, 2024
Lilly’s Morphic Acquisition; IDEAYA’s IDE397 Positive Phase II Trial Result; XPOVIO (selinexor) Approval in China; Roche to Reintroduce Susvimo in the US; Dupixent EU Approval
Lilly Strengthens IBD Treatment Portfolio with Morphic Acquisition Eli Lilly and Company and Morphic Holding, Inc. announced a definitive agreement for Lilly to acquire Morphic, a biopharmaceutical company developing oral integrin therapies for serious chronic diseases. Lilly will initiate a tender offer to acqu...
Read More...
Jul 08, 2024
A New Dawn in Alzheimer’s Disease Treatment: Eli Lilly’s Donanemab Wins FDA Approval
The world of Alzheimer’s disease treatment witnessed a groundbreaking moment recently as the FDA approved Eli Lilly’s donanemab, marketed as KISUNLA. This new drug brings hope to millions of patients and their families struggling with this debilitating disease. Let us delve into the fascinating journey of donanemab...
Read More...
Jul 05, 2024
Oncolytic Virus Cancer Therapy: Transforming Cancer Treatment
Oncolytic viruses (OVs) represent a new category of cancer treatments that provide several advantages: they selectively replicate within tumor cells, can deliver various eukaryotic transgene payloads, induce immunogenic cell death, enhance antitumor immunity, and generally have a safe profile that doesn't significa...
Read More...
Jul 04, 2024
Artivion and Endospan Agreement; Masimo and Cleveland Clinic Collaboration; Academic Medical Center’s Sedation-Free TNE With the EvoEndo Endoscopy System; IceCure’s Next-Gen XSenseTM Cryoablation System FDA Approval; KORU Medical Systems’ Clearance for FreedomEdge® Infusion System; Reflow Medical’s First Patient in Coronary Sirolimus-Eluting Retrievable Scaffold System
Artivion Amended Agreements With Endospan On June 01, 2024, Artivion, Inc. a prominent company in cardiac and vascular surgery specializing in aortic disease, announced that it revised its credit facility and option purchase agreements with Endospan Ltd. ("Endospan"), an Israeli-based, privately-held developer o...
Read More...
Jul 03, 2024
The Rise of Energy Drinks: Power in a Can or a Health Hazard?
Energy drinks have become a ubiquitous part of modern life, promising quick boosts of energy, enhanced mental alertness, and improved physical performance. These beverages are particularly popular among young adults, athletes, and professionals who often face demanding schedules and high levels of stress. However, ...
Read More...
Jul 02, 2024
Eisai Announces Solo Development of Farletuzumab Ecteribulin (FZEC); Johnson & Johnson’s Nipocalimab Phase III Trial; Merck’s WINREVAIR EU CHMP Recommendation; Verona Pharma’s Ohtuvayre FDA Approval; AstraZeneca’s Lynparza and Imfinzi EU Approval
Eisai Announces Solo Venture for Farletuzumab Ecteribulin (FZEC) Antibody Drug Conjugate Eisai Co., Ltd. announced the termination of its global strategic collaboration with Bristol Myers Squibb for the co-development and co-commercialization of farletuzumab ecteribulin (FZEC), previously known as MORAb-202, an ...
Read More...